EA202190647A1 - Антитела к klrg1 - Google Patents

Антитела к klrg1

Info

Publication number
EA202190647A1
EA202190647A1 EA202190647A EA202190647A EA202190647A1 EA 202190647 A1 EA202190647 A1 EA 202190647A1 EA 202190647 A EA202190647 A EA 202190647A EA 202190647 A EA202190647 A EA 202190647A EA 202190647 A1 EA202190647 A1 EA 202190647A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
klrg1
antigen
binding fragments
lectin
Prior art date
Application number
EA202190647A
Other languages
English (en)
Inventor
Стефано В. Гулла
Кеннет Эван Томпсон
Original Assignee
Абкуро, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Абкуро, Инк. filed Critical Абкуро, Инк.
Publication of EA202190647A1 publication Critical patent/EA202190647A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к антителам или их антигенсвязывающим фрагментам, которые специфически связываются с лектиноподобным рецептором G1 клеток-киллеров (KLRG1). Такие антитела или их антигенсвязывающие фрагменты пригодны для различных терапевтических или диагностических целей, включая лечение раковых заболеваний и повышение эффективности вакцин.
EA202190647A 2018-09-17 2019-09-06 Антитела к klrg1 EA202190647A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862732329P 2018-09-17 2018-09-17
PCT/US2019/050110 WO2020060781A1 (en) 2018-09-17 2019-09-06 Anti-klrg1 antibodies

Publications (1)

Publication Number Publication Date
EA202190647A1 true EA202190647A1 (ru) 2021-09-09

Family

ID=69887899

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190647A EA202190647A1 (ru) 2018-09-17 2019-09-06 Антитела к klrg1

Country Status (13)

Country Link
US (1) US20210347899A1 (ru)
EP (1) EP3852779A4 (ru)
JP (1) JP2022501065A (ru)
KR (1) KR20210060477A (ru)
CN (1) CN112752580A (ru)
AU (1) AU2019344524A1 (ru)
BR (1) BR112021004553A2 (ru)
CA (1) CA3113069A1 (ru)
EA (1) EA202190647A1 (ru)
IL (1) IL281594A (ru)
MX (1) MX2021003119A (ru)
SG (1) SG11202102114UA (ru)
WO (1) WO2020060781A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022056289A1 (en) * 2020-09-11 2022-03-17 National Jewish Health Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells
CA3212311A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
WO2022204529A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
WO2024072872A2 (en) * 2022-09-27 2024-04-04 The Brigham And Women's Hospital, Inc. Klrg1 signalling therapy for infectious disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008083174A2 (en) * 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
WO2012031099A2 (en) * 2010-09-02 2012-03-08 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
US9127061B2 (en) * 2011-06-24 2015-09-08 Perseus Proteomics Inc. Anti-human P-cadherin (CDH3) recombinant antibody
JP2017518958A (ja) * 2014-03-19 2017-07-13 マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルＭａｃｋａｙ Ｍｅｄｉｃａｌ Ｆｏｕｎｄａｔｉｏｎ Ｔｈｅ Ｐｒｅｓｂｙｔｅｒｉａｎ Ｃｈｕｒｃｈ Ｉｎ Ｔａｉｗａｎ Ｍａｃｋａｙ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
EP3471539A4 (en) * 2016-06-03 2020-02-26 The Brigham and Women's Hospital SIGNALING PROCESSING WITH KLRG1
AU2017326003A1 (en) * 2016-09-16 2019-04-11 Children's Medical Center Corporation KLRG1 depletion therapy

Also Published As

Publication number Publication date
CN112752580A (zh) 2021-05-04
US20210347899A1 (en) 2021-11-11
WO2020060781A1 (en) 2020-03-26
EP3852779A1 (en) 2021-07-28
BR112021004553A2 (pt) 2021-06-08
AU2019344524A1 (en) 2021-03-25
EP3852779A4 (en) 2022-06-08
IL281594A (en) 2021-05-31
JP2022501065A (ja) 2022-01-06
MX2021003119A (es) 2021-05-14
SG11202102114UA (en) 2021-04-29
KR20210060477A (ko) 2021-05-26
CA3113069A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
EA202190647A1 (ru) Антитела к klrg1
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
EA202092605A1 (ru) Антитела к ил-11ra
EA201791171A1 (ru) Антитела к tigit
EA202092668A1 (ru) Антитела к ил-11
EA201691482A1 (ru) Человеческие антитела к pd-1
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
EA201991546A1 (ru) Антигенсвязывающие белки против нейропилина и способы их применения
MX2020008122A (es) Anticuerpos anti-pd-1.
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA202092302A1 (ru) Антитела к trem-1 и их применения
EA202092420A1 (ru) Антитело против pd-l1 и его применение
EA201990988A1 (ru) Антитела против chikv и пути их применения
EA202190807A1 (ru) Антитела к синуклеину
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
EA201990895A1 (ru) Антитела к о1 и варианты их применения
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
EA202090387A1 (ru) Белки, связывающие nkg2d, cd16 и flt3
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения